Brian Levy
Directeur Général chez InflammX Therapeutics, Inc.
Profil
Brian Levy is currently the Chief Executive Officer & Director at OcuNexus Therapeutics, Inc., the Chief Executive Officer & Director at InflammX Therapeutics, Inc. since 2020, a Professor at the University of Rochester Medical Center since 2014, and an Advisor at Spindletop Capital Management LLC.
Previously, he served as an Independent Director at InSite Vision, Inc. from 2011 to 2015, a Director at Astellas Institute for Regenerative Medicine from 2015 to 2016, the Chief Medical Officer, VP-Research & Development at Bausch & Lomb, Inc. from 1994 to 2008, the Chief Medical Officer at Aerie Pharmaceuticals, Inc. from 2012 to 2015, the Chief Operating & Scientific Officer at Danube Pharmaceuticals, Inc. from 2012 to 2013, and an Associate Professor at California Pacific Medical Center from 1989 to 1994.
He also served as the Chief Scientific Officer at Nexis Vision, Inc. in 2011.
Dr. Levy holds a graduate degree from The University of Waterloo (1979) and a doctorate degree from the University of California, Berkeley (1976).
Postes actifs de Brian Levy
| Sociétés | Poste | Début |
|---|---|---|
University of Rochester Medical Center
 University of Rochester Medical Center Other Consumer ServicesConsumer Services University of Rochester Medical Center operates a medical center which offers healthcare, education and research services. It offers funding in biochemistry, microbiology and immunology, neurology, obstetrics and gynecology, oral biology and musculoskeletal research services. The firm’s departments include AIDS Center, Audiology and Aab Cardiovascular Research Institute. The company was founded by Abraham Flexner and Benjamin Rush Rhees in 1921 and is headquartered in Rochester, NY. | Corporate Officer/Principal | - |
OcuNexus Therapeutics, Inc.
 OcuNexus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA. | Directeur Général | - |
InflammX Therapeutics, Inc.
 InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | Directeur Général | 01/01/2020 |
Spindletop Capital Management LLC
 Spindletop Capital Management LLC Investment ManagersFinance Spindletop Capital Management LLC (Spindletop Capital) is a private equity/venture capital firm founded in 2011. The firm is headquartered in Austin, Texas. | Consultant / Advisor | - |
Anciens postes connus de Brian Levy
| Sociétés | Poste | Fin |
|---|---|---|
| OCATA THERAPEUTICS INC | Directeur/Membre du Conseil | 10/02/2016 |
| INSITE VISION INC. | Directeur/Membre du Conseil | 02/11/2015 |
| AERIE PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 07/07/2015 |
Nexis Vision, Inc.
 Nexis Vision, Inc. Medical SpecialtiesHealth Technology Nexis Vision, Inc. develops ophthalmic solutions. The company was founded in 2007 and is headquartered in Menlo Park, CA. | Directeur Technique/Scientifique/R&D | 01/10/2011 |
Bausch & Lomb, Inc.
 Bausch & Lomb, Inc. Medical SpecialtiesHealth Technology Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY. | Directeur Technique/Scientifique/R&D | - |
Formation de Brian Levy
| University of California, Berkeley | Doctorate Degree |
| The University of Waterloo | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Danube Pharmaceuticals, Inc.
 Danube Pharmaceuticals, Inc. BiotechnologyHealth Technology Danube Pharmaceuticals, Inc. provides bio pharmaceutical services. It engages in the discovery and development of therapies and devices for ophthalmology. The firm's products include DNB-001, a small molecule for the treatment of glaucoma. The company was founded in 2006 and is headquartered in New York, NY. | Health Technology |
InSite Vision, Inc.
 InSite Vision, Inc. Pharmaceuticals: MajorHealth Technology InSite Vision Inc. develops and markets ophthalmic pharmaceutical products that designs to treat a range of common eye problems, including ocular infection, pain and inflammation in ocular surgery, and glaucoma. Its products include AzaSite, Besivance, AzaSite Plus, DexaSite, AzaSite Xtra, and ISV-10 and 303. The company was founded by Merwin Jerry Hansen in 1986 and is headquartered in Alameda, CA. | Health Technology |
Aerie Pharmaceuticals, Inc.
 Aerie Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on January 1, 2005 and is headquartered in Durham, NCForth Worth, TX. | Health Technology |
California Pacific Medical Center
 California Pacific Medical Center Miscellaneous Commercial ServicesCommercial Services California Pacific Medical Center operates medical centers. It offers acute and specialty care services including obstetrics, gynecology, cardiovascular, pediatrics, neurosciences, orthopedics, and organ transplantation. The company is headquartered in San Francisco, CA. | Commercial Services |
Bausch & Lomb, Inc.
Bausch & Lomb, Inc. Medical SpecialtiesHealth Technology Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY. | Health Technology |
Nexis Vision, Inc.
Nexis Vision, Inc. Medical SpecialtiesHealth Technology Nexis Vision, Inc. develops ophthalmic solutions. The company was founded in 2007 and is headquartered in Menlo Park, CA. | Health Technology |
Astellas Institute for Regenerative Medicine
 Astellas Institute for Regenerative Medicine Pharmaceuticals: MajorHealth Technology Astellas Institute for Regenerative Medicine engages in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine. The company also have a preclinical development pipeline in areas outside of ophthalmology, including; autoimmune diseases, inflammatory diseases, and wound healing. The company was founded on May 18, 2000 and is headquartered in Marlborough, MA. | Health Technology |
OcuNexus Therapeutics, Inc.
OcuNexus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA. | Health Technology |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | Commercial Services |
Spindletop Capital Management LLC
Spindletop Capital Management LLC Investment ManagersFinance Spindletop Capital Management LLC (Spindletop Capital) is a private equity/venture capital firm founded in 2011. The firm is headquartered in Austin, Texas. | Finance |
